Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
Hyun S KimWalid L ShaibChao ZhangGanji Purnachandra NagarajuChristina WuOlatunji B AleseZhengjia ChenEdith BrutcherMeredith RenfroeBassel F El-RayesPublished in: Cancer (2018)
The recommended phase 2 dose of everolimus is 10 mg daily in combination with pasireotide and SIRT. The regimen is well tolerated. Preliminary activity appears promising. Cancer 2018;124:1992-2000. © 2018 American Cancer Society.